Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2002 Sep 2;196(5):579–588. doi: 10.1084/jem.20011255

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2002, The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 1. — Bulk culture recognition of PUUV proteins. PBMCs (4–5 × 10⁶) were stimulated with 20 μl of infectious PUUV (strain K27; 2.6 × 10⁶ pfu/ml) and cytotoxicity assays were performed using autologous BLCLs infected with recombinant vaccinia viruses expressing PUUV N, G1, G2/Bs or G2/Sm protein as targets. The recombinant vaccinia virus designated vac-G2/Bs contains the first half of the G2 cDNA (amino acids 1 to 256), and the recombinant designated vac-G2/Sm contains the second half of the G2 protein (amino acids 227 to 490). E/T ratios were either 60:1 or 80:1. Unlabeled wild-type vaccinia virus infected BLCL were included in all wells at a ratio of 10:1 unlabeled: labeled targets, to reduce levels of vaccinia virus-specific lysis. Data shown represent the percent specific lysis after subtraction of wild-type vaccinia virus background lysis. Responses >10% above background were considered positive.